Survodutide vs Gonadorelin
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SurvodutideSexual Health & LibidoAnti-Aging & Longevity
Gonadorelin- Summary
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Gonadorelin is the synthetic form of endogenous GnRH (gonadotropin-releasing hormone). It stimulates the pituitary to release LH and FSH, maintaining testicular function and testosterone production. Widely used alongside TRT to prevent testicular atrophy and preserve fertility.
- Half-Life
- ~7 days
- ~2–4 minutes (extremely short); pulsatile dosing required to avoid desensitization
- Admin Route
- SubQ
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- 100 mcg
- Frequency
- Once weekly
- Twice daily (every 12 hours)
- Key Benefits
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Maintains testicular size during TRT
- Preserves fertility and sperm production during testosterone use
- Stimulates endogenous LH/FSH production
- Maintains HPG axis function during exogenous hormone use
- Used for HCG-free TRT protocols
- Helps restart natural testosterone production (PCT)
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Injection site reactions
- Headache
- Nausea at initiation
- Tachycardia (rare)
- +1 more
- Stacks With
- —
- —